Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Methotrexate-associated lymphoproliferative disorders are rare immunodeficiency-associated lymphoproliferative diseases characterized by lymphoid proliferation or lymphomas (large B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma, reactive lymphadenitis and a polymorphic post-transplant lymphoproliferative disorder) that develop in patients with different autoimmune diseases treated with methotrexate. Swelling is the predominant manifestation of the disease and regression after methotrexate withdrawal is observed in a significant proportion of patients.
Biomarker and diagnostic research for methotrexate-associated lymphoproliferative disorders has been reported in the published literature.
No clinical trials have been registered for methotrexate-associated lymphoproliferative disorders.
31 publications have been identified in PubMed for methotrexate-associated lymphoproliferative disorders. Research spans Case Report / Case Series (90%), Diagnostic / Biomarker (3%), and Clinical Trial Publication (3%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 28 | 90% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 12:50 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Testing and diagnosis research |
1 |
3% |
Clinical study results | 1 | 3% |
Laboratory research | 1 | 3% |
Minta M (2026). [PMID: 42139094](https://pubmed.ncbi.nlm.nih.gov/42139094/). *Mod Rheumatol Case Rep*. [Case Report / Case Series]
Watanabe R (2026). [PMID: 41685059](https://pubmed.ncbi.nlm.nih.gov/41685059/). *Cureus*. [Case Report / Case Series]
Arai K (2026). [PMID: 41613995](https://pubmed.ncbi.nlm.nih.gov/41613995/). *Case reports in medicine*. [Case Report / Case Series]
Yasuda H (2026). [PMID: 42021033](https://pubmed.ncbi.nlm.nih.gov/42021033/). *Intern Med*. [Case Report / Case Series]
Edagawa T (2025). [PMID: 39048370](https://pubmed.ncbi.nlm.nih.gov/39048370/). *Internal medicine (Tokyo, Japan)*. [Case Report / Case Series]
Murasawa S (2025). [PMID: 41433192](https://pubmed.ncbi.nlm.nih.gov/41433192/). *Endocrinology, diabetes & metabolism case reports*. [Case Report / Case Series]
Shigenobu S (2025). [PMID: 40500207](https://pubmed.ncbi.nlm.nih.gov/40500207/). *Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology*. [Case Report / Case Series]
Masuta Y (2025). [PMID: 40835474](https://pubmed.ncbi.nlm.nih.gov/40835474/). *Internal medicine (Tokyo, Japan)*. [Case Report / Case Series]
Arisumi S (2025). [PMID: 41384778](https://pubmed.ncbi.nlm.nih.gov/41384778/). *Modern rheumatology*. [Case Report / Case Series]
Mochizuki T (2025). [PMID: 39657696](https://pubmed.ncbi.nlm.nih.gov/39657696/). *Modern rheumatology case reports*. [Case Report / Case Series]
AI-curated news mentioning methotrexate-associated lymphoproliferative disorders
Updated May 13, 2026
Recent research highlights how FAS-controlled T cells promote lymphoproliferation via glycolysis, bypassing typical effector differentiation. This discovery could inform future therapeutic strategies for related conditions.
A new study explores the pathobiology and diagnostic challenges of lymphoproliferative disorders following CAR T cell therapy. The research provides mechanistic insights that could inform future therapeutic strategies.